Revenue: The sum of all revenue fields included for a company's operating activities.
Halozyme Therapeutics, Inc. (HALO) had Revenue of $451.77M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
|
Revenue |
$451.77M |
$-141.59M |
|
$78.77M |
|
$373.00M |
|
$544.66M |
|
$-92.89M |
|
$-7.96M |
|
$-100.85M |
|
$-100.85M |
|
$-141.59M |
|
$-141.59M |
|
$-141.59M |
|
$-141.59M |
|
$-92.89M |
|
$-64.36M |
|
119.84M |
|
123.90M |
|
$-1.17 |
|
$-1.13 |
|
| Balance Sheet Financials | |
$825.21M |
|
$82.14M |
|
$1.70B |
|
$2.53B |
|
$177.09M |
|
$2.14B |
|
$2.30B |
|
$2.48B |
|
$48.81M |
|
$-1.51B |
|
$48.81M |
|
117.78M |
|
| Cash Flow Statement Financials | |
$651.56M |
|
$-545.81M |
|
$-85.17M |
|
$115.85M |
|
$136.42M |
|
$20.57M |
|
$51.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.66 |
|
-- |
|
-- |
|
0.98 |
|
43.89 |
|
82.56% |
|
-20.56% |
|
-20.56% |
|
-- |
|
-22.32% |
|
-31.34% |
|
$644.59M |
|
-- |
|
-- |
|
-- |
|
0.18 |
|
0.45 |
|
1.02 |
|
87.91 |
|
-290.06% |
|
9.36% |
|
-5.61% |
|
-6.46% |
|
$0.41 |
|
$5.20 |
|
$5.26 |
|